Johnson & Johnson is preparing regulatory submissions for icotrokinra, its first-in-class oral therapy for psoriasis, after the drug hit its main goals in two Phase III studies.
Key Takeaways
J&J's interleukin-23 receptor blocker has hit in two Phase III psoriasis trials, with regulatory filings planned.
The once-daily pill could provide strong competition...
Icotrokinra, a once-daily oral peptide that blocks the interleukin-23 receptor which J&J licensed from Protagonist Therapeutics in 2017, has met its co-primary endpoints in patients with moderate to severe plaque...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?